Market watch: upcoming market catalysts in Q3 2010.
Hay
Michael
M
D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001552:Benzazepines / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D004338:Drug Combinations; D004353:Drug Evaluation, Preclinical; D005632:Fructose / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D010645:Phentermine / Q000627:therapeutic use; D000077236:Topiramate; D014481:United States; D014486:United States Food and Drug Administration
D019440:Anti-Obesity Agents; D001552:Benzazepines; D004338:Drug Combinations; D000077236:Topiramate; D005632:Fructose; C506658:lorcaserin; D010645:Phentermine